<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419636</url>
  </required_header>
  <id_info>
    <org_study_id>18454A</org_study_id>
    <nct_id>NCT04419636</nct_id>
  </id_info>
  <brief_title>Binding of Lu AG06466 in the Brain in Healthy Men</brief_title>
  <official_title>Interventional, Open-label, Position Emission Tomography (PET) Study Investigating MAGL Occupancy After Single and Multiple Oral Doses of Lu AG06466 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to learn how Lu AG06466 and one of its break down products binds in the brain after
      single and repeated dosing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two Parts. Part A: cross over, fed/fasted determined by
      randomized sequence Part B: sequential group

      PET scans will be used to quantify MAGL occupancy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central monoacylglycerol lipase (MAGL) occupancy</measure>
    <time_frame>From dosing to 8 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C(PET)</measure>
    <time_frame>From zero to Day 10</time_frame>
    <description>Average plasma concentration for Lu AG06466 and Lu AG06988 during PET imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-24)</measure>
    <time_frame>From zero to 24 hours post-dose</time_frame>
    <description>Area under the plasma concentration curve for Lu AG06466 and Lu AG06988 from zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From zero to 24 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration for Lu AG06466 and Lu AG06988</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A Single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AG06466 in fast and fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Repeated doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AG06466 after light meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466</intervention_name>
    <description>capsules, orally</description>
    <arm_group_label>Part A Single doses</arm_group_label>
    <arm_group_label>Part B Repeated doses</arm_group_label>
    <other_name>ABX-1431</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body weight ≥60 kg.

          -  body mass index ≥18.5 and ≤27 kg/m2.

          -  waist circumference ≤94 cm.

          -  The subject has a normal sMRI performed during the screening period.

          -  The subject is suitable for radial artery blood sampling and cannulation as
             demonstrated by the Allen test.

          -  Subject must be healthy as assessed using detailed medical history, laboratory tests,
             and physical examination.

          -  The subject must make use of contraception.

        Exclusion Criteria:

          -  The subject is left handed.

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Email contact via H. Lundbeck A/S</last_name>
      <phone>+45 36301311</phone>
      <email>LundbeckClinicalTrials@Lundbeck.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

